The overall goal of this natural history study is to define the key LGMD2i phenotypes as measured by standard clinical outcome assessments (COAs), and to validate a muscle biomarker for LGMD2i to support therapeutic development.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
10-Meter walk (10 MWT) -mobility
Timeframe: Through study completion at 12 months
100-Meter Timed Test (100m) - mobility
Timeframe: Through study completion at 12 months
NSAD- Motor performance
Timeframe: Through study completion at 12 months
Timed up-and-go (TUG) - mobility
Timeframe: Through study completion at 12 months
FVC - Pulmonary function
Timeframe: Through study completion at 12 months
Timed 4 stair Climb (4SC) - mobility
Timeframe: Through study completion at 12 months
9 Hole Peg Test (9HPT) - distal upper extremity function
Timeframe: Through study completion at 12 months
Performance of Upper Limb (PUL 2.0) - limb function
Timeframe: Through study completion at 12 months
Hand Held Dynamometry (HHD) - isometric strength
Timeframe: Through study completion at 12 months